A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians

Background. A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to control epidemic group A meningitis in Africa. Documentation of the safety specifications of the PsA-TT vaccine was warranted, with sufficient exposure to detect potential r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Infect Dis
Main Authors: Tapia, Milagritos D., Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Enwere, Godwin C., Paranjape, Gandhali, Hervé, Jacques, Bouma, Enricke, Parulekar, Varsha, Martellet, Lionel, Chaumont, Julie, Plikaytis, Brian D., Tang, Yuxiao, Kulkarni, Prasad S., Hartmann, Katharina, Preziosi, Marie-Pierre
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2015
Assuntos:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639507/
https://ncbi.nlm.nih.gov/pubmed/26553682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ626
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares